Peripheral Artery Disease and Vascular Conditions

Peripheral artery disease (PAD) and related vascular conditions represent a significant cardiovascular burden in the United States, affecting the arterial supply to limbs, the renal system, and the mesenteric circulation. This page covers the definition and classification of PAD, the underlying atherosclerotic mechanism, the clinical scenarios in which it presents, and the decision boundaries that guide diagnosis and intervention. Understanding these conditions is essential context within the broader landscape of cardiovascular medicine.

Definition and scope

Peripheral artery disease is defined by the narrowing or occlusion of arteries outside the coronary and intracranial circuitry — most commonly the arteries supplying the lower extremities. The American Heart Association (AHA) and American College of Cardiology (ACC) jointly define PAD in their 2024 Peripheral Artery Disease Guideline as a manifestation of systemic atherosclerosis that confers elevated risk not only for limb loss but for myocardial infarction and stroke.

The ankle-brachial index (ABI) serves as the primary noninvasive diagnostic threshold. The ACC/AHA guideline classifies an ABI of 0.90 or below as abnormal, indicating hemodynamically significant arterial obstruction. An ABI above 1.40 is also considered abnormal and suggests noncompressible, calcified vessels — a pattern common in patients with long-standing diabetes mellitus or chronic kidney disease.

PAD's scope extends beyond the lower extremities. Major vascular territories affected include:

  1. Lower extremity arteries — iliac, femoral, popliteal, and tibial vessels
  2. Renal arteries — stenosis that can drive secondary hypertension and accelerated renal decline
  3. Mesenteric arteries — responsible for intestinal ischemia when significantly narrowed
  4. Carotid and vertebral arteries — classified separately as cerebrovascular disease but sharing the same atherosclerotic pathophysiology

The regulatory context for cardiology in the United States involves multiple oversight bodies, including the Centers for Medicare & Medicaid Services (CMS), which sets reimbursement criteria and quality metrics for PAD diagnosis and management under Medicare's Physician Fee Schedule.

How it works

The dominant mechanism underlying PAD is atherosclerosis — the progressive accumulation of lipid-laden plaques within arterial walls. Endothelial dysfunction initiates the cascade: circulating low-density lipoprotein (LDL) particles penetrate the intimal layer, oxidize, and trigger an inflammatory response mediated by macrophage-derived foam cells. Over time, fibrous caps form over lipid cores, narrowing the vessel lumen and reducing blood flow.

In the lower extremities, this process most frequently affects the superficial femoral artery at the adductor canal — the longest and most mechanically stressed segment of the femoral system. As stenosis exceeds roughly 50% of the vessel lumen, the pressure gradient across the lesion begins to impair flow during exercise. When stenosis approaches 70% or greater, resting blood flow can become compromised.

Collateral circulation can partially compensate for gradual occlusion, which explains why chronic total occlusions of the superficial femoral artery sometimes present with relatively mild symptoms while acute thrombotic occlusion of the same vessel produces limb-threatening ischemia.

The National Heart, Lung, and Blood Institute (NHLBI) identifies cigarette smoking, diabetes mellitus, hypertension, and hyperlipidemia as the four strongest modifiable risk factors for PAD (NHLBI PAD overview). Smoking confers a risk increase of approximately 3- to 4-fold for developing PAD compared with nonsmokers, according to epidemiologic data summarized in the ACC/AHA guidelines.

Common scenarios

PAD presents across a spectrum of clinical severity. The Rutherford classification system, widely referenced in vascular medicine, divides chronic limb ischemia into 6 categories (0 through 6), with Category 0 indicating asymptomatic disease and Category 6 representing major tissue loss.

Asymptomatic PAD is frequently detected incidentally during ABI screening in high-risk populations. The U.S. Preventive Services Task Force (USPSTF) has evaluated ABI screening in asymptomatic adults and found insufficient evidence to recommend universal screening, though targeted screening is supported in patients with diabetes over age 50 or those with multiple cardiovascular risk factors (USPSTF final recommendation statement on PAD).

Intermittent claudication is the classic symptomatic presentation — reproducible cramping or fatigue in the calf, thigh, or buttock during walking, relieved by rest within 10 minutes. The pain-free walking distance decreases progressively as disease advances. Claudication in the calf implicates femoral-popliteal disease; buttock and thigh claudication implicates aortoiliac obstruction (Leriche syndrome).

Chronic limb-threatening ischemia (CLTI) — the most severe form of PAD — is defined by ischemic rest pain, non-healing ulcers, or gangrene present for more than 2 weeks. The CLTI designation replaced the older term "critical limb ischemia" following the 2019 Global Vascular Guidelines published in the Journal of Vascular Surgery, which also introduced the WIFI classification (Wound, Ischemia, foot Infection) to standardize limb staging (Global Vascular Guidelines on CLTI, 2019).

Acute limb ischemia (ALI) represents a vascular emergency defined by the sudden onset of the "6 Ps": pain, pallor, pulselessness, paresthesias, paralysis, and poikilothermia. ALI carries an amputation risk that rises significantly beyond the 6-hour window from symptom onset if revascularization is not achieved.

Decision boundaries

The ACC/AHA 2024 guidelines provide a tiered framework for management decisions based on lesion anatomy, severity category, and patient comorbidities.

Medical management alone is appropriate for asymptomatic PAD and mild-to-moderate claudication. Guideline-directed medical therapy (GDMT) includes antiplatelet therapy (aspirin or clopidogrel), high-intensity statin therapy, blood pressure control, smoking cessation, and supervised exercise therapy. The ACC/AHA assign supervised exercise a Class I (strong) recommendation for claudication — equivalent in evidence weight to revascularization for that indication.

Revascularization is indicated when GDMT fails to adequately relieve claudication, when CLTI is present, or when ALI requires emergency intervention. The choice between endovascular and surgical revascularization follows the Trans-Atlantic Inter-Society Consensus (TASC II) anatomic classification:

Endovascular options include percutaneous transluminal angioplasty (PTA), drug-coated balloon angioplasty, bare-metal or drug-eluting stenting, and atherectomy. Surgical options include aortobifemoral bypass, femoral-popliteal bypass (with autologous saphenous vein preferred over prosthetic graft below the knee), and femoral-tibial bypass for distal disease.

Patients with PAD should undergo formal cardiac stress testing before major vascular surgery, as coronary artery disease is present in a substantial proportion of the PAD population — with some series reporting coronary disease in more than 50% of patients presenting for lower extremity revascularization.

Amputation is reserved for non-salvageable limbs — those with extensive tissue loss, uncontrolled infection, or absent viable revascularization targets. Major amputation rates vary by institution but remain a tracked quality metric under CMS's Inpatient Quality Reporting Program.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)